Trial Profile
AFIRE Study: Atrial Fibrillation and Ischemic events with Rivaroxaban in patiEnts with stable coronary artery disease Study
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel; Prasugrel
- Indications Cardiovascular disorders; Myocardial infarction; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms AFIRE Study
- 29 Aug 2022 Results of post-hoc analysis assessing outcomes of rivaroxaban monotherapy (vs. combination therapy) in patients with atrial fibrillation and stable coronary artery disease across body mass index categories, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
- 13 Jun 2022 Results published in the Thrombosis and Haemostasis
- 14 Jul 2021 Results (n= 1075) of pre-specified sub-analysis assessing efficacy and safety of P2Y12 inhibitors and aspirin in patients with stable CAD and AF, published in the Heart.